Cargando…

Barriers to non-small cell lung cancer trial eligibility

INTRODUCTION: Cancer clinical trial (CCT) enrollment is low potentially threatening the generalizability of trial results and expedited regulatory approvals. We assessed whether type of initial patient appointment for non-small cell lung cancer (NSCLC) is associated with CCT eligibility. METHODS: Us...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hardesty, Jeffrey J., Kanarek, Norma F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898521/ https://www.ncbi.nlm.nih.gov/pubmed/29696224 http://dx.doi.org/10.1016/j.conctc.2017.11.010

Ejemplares similares

The effect of prior cancer on non‐small cell lung cancer trial eligibility
por: Herman, Michael, et al.
Publicado: (2021)

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
por: Vardy, Janette, et al.
Publicado: (2009)

Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study
por: Kanarek, Norma F, et al.
Publicado: (2012)

Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study
por: Boys, Emma, et al.
Publicado: (2023)

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
por: Kodama, Hiroaki, et al.
Publicado: (2021)

Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
por: Fujimoto, Daichi, et al.
Publicado: (2023)

Eligibility for Bevacizumab as an Independent Prognostic Factor for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study
por: Takagi, Yusuke, et al.
Publicado: (2013)

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
por: Vergnenègre, Alain, et al.
Publicado: (2019)

Barriers, Facilitators, and Suggested Interventions for Lung Cancer Screening Among a Rural Screening-Eligible Population
por: Schiffelbein, Jenna E., et al.
Publicado: (2020)

Lung Cancer Care Before and After Medicare Eligibility
por: Huesch, Marco D., et al.
Publicado: (2016)

Assessment of Biomarker Testing for Lung Cancer Screening Eligibility
por: Larose, Tricia L., et al.
Publicado: (2020)

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
por: Rittberg, Rebekah, et al.
Publicado: (2022)

Inclusion of Evidence-Based Breast Cancer Control Recommendations and Guidelines in State Comprehensive Cancer Control Plans
por: Soori, Mehrnoosh, et al.
Publicado: (2020)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom
por: Robbins, Hilary A., et al.
Publicado: (2021)

Implementation Barriers and Experiences of Eligible Patients Who Failed to Enroll in Collaborative Care for Depression and Anxiety
por: Fu, Emily, et al.
Publicado: (2022)

Improving lung cancer screening: An equitable strategy through a tobacco treatment clinic
por: Galiatsatos, Panagis, et al.
Publicado: (2021)

Analysis of Eligibility Criteria Complexity in Clinical Trials
por: Ross, Jessica, et al.
Publicado: (2010)

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates
por: Eichkorn, Tanja, et al.
Publicado: (2020)

Eligibility for Lung Cancer Screening Among Women Receiving Screening for Breast Cancer
por: Titan, Ashley L., et al.
Publicado: (2022)

Eligibility of real-world patients with metastatic breast cancer for clinical trials
por: Batra, Atul, et al.
Publicado: (2020)

Eligibility criteria in clinical trials in breast cancer: a cohort study
por: Szlezinger, Katarzyna, et al.
Publicado: (2023)

Dynamic transition of the blood-brain barrier in the development of non-small cell lung cancer brain metastases
por: Uzunalli, Gozde, et al.
Publicado: (2019)

Endobronchial Ultrasound/Transbronchial Needle Aspiration-Biopsy for Systematic Mediastinal lymph Node Staging of Non-Small Cell Lung Cancer in Patients Eligible for Surgery: A Prospective Multicenter Study
por: Divisi, Duilio, et al.
Publicado: (2023)

Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer
por: Chae, Young Kwang, et al.
Publicado: (2018)

Do Lung Cancer Eligibility Criteria Align with Risk among Blacks and Hispanics?
por: Fiscella, Kevin, et al.
Publicado: (2015)

Methods for Using Race and Ethnicity in Prediction Models for Lung Cancer Screening Eligibility
por: Landy, Rebecca, et al.
Publicado: (2023)

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
por: Rittberg, Rebekah, et al.
Publicado: (2022)

Non–evidence-based platelet transfusions for protocol eligibility
por: Vossoughi, Sarah, et al.
Publicado: (2020)

Changing the landscape of non-small cell lung cancer disparities
por: Odera, Joab O., et al.
Publicado: (2021)

A modeling analysis to compare eligibility strategies for lung cancer screening in Brazil
por: Miranda-Filho, Adalberto, et al.
Publicado: (2021)

Chemotherapy of non-small cell lung cancer.
por: Williams, C. J.
Publicado: (1989)

The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer
por: Middleton, G., et al.
Publicado: (2015)

How Have Cancer Clinical Trial Eligibility Criteria Evolved Over Time?
por: Yaman, Anil, et al.
Publicado: (2016)

Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer
por: Rice, Shawn J., et al.
Publicado: (2021)

Prevalence of Lung Cancer Screening Among Eligible Adults in 4 US States in 2021
por: Maki, Kristin G., et al.
Publicado: (2023)

Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P.A., et al.
Publicado: (2019)

The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer.
por: Mackillop, W. J., et al.
Publicado: (1986)

A review of research on eligibility criteria for clinical trials
por: Su, Qianmin, et al.
Publicado: (2023)

Eligible-and-enrolled vs. eligible-but-not-enrolled patients with chronic ischaemic heart failure in randomized clinical trials of myocardial regeneration
por: Czyż, Łukasz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fpqmv6dgeviqror5rasea8j1k5